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Abstract
GPR56 is a member of the adhesion G protein-coupled receptor (GPCR) family. Mutations in GPR56 cause a devastating
human brain malformation called bilateral frontoparietal polymicrogyria (BFPP). Using the N-terminal fragment of GPR56
(GPR56
N) as a probe, we have recently demonstrated that collagen III is the ligand of GPR56 in the developing brain. In this
report, we discover a new functional domain in GPR56
N, the ligand binding domain. This domain contains four disease-
associated mutations and two N-glycosylation sites. Our study reveals that although glycosylation is not required for ligand
binding, each of the four disease-associated mutations completely abolish the ligand binding ability of GPR56. Our data
indicates that these four single missense mutations cause BFPP mostly by abolishing the ability of GPR56 to bind to its
ligand, collagen III, in addition to affecting GPR56 protein surface expression as previously shown.
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Introduction
Adhesion GPCRs are a relatively new family of GPCRs that
h a v eav e r yl o n gN - t e r m i n a le x t r a c e l l u l a rd o m a i n .I nh u m a n s ,
there are a total of 33 members of adhesion GPCRs that are
thought to mediate cell-cell and cell-extracellular matrix
interaction, with GPR56 as the first one linked to a human
developmental malformation [1,2]. Mutations in GPR56 cause
BFPP, a specific human brain malformation [3,4]. To date, a
total of fourteen BFPP-associated mutations have been identi-
fied, including one deletion, two splicing, and eleven missense
mutations [2,5]. Based on the fact that all of the missense
mutations render an identical clinical phenotype as the deletion
mutation, it is presumed that all missense mutations result in a
null allele [4]. Previously, we have shown that all of the missense
mutations affect GPR56 protein trafficking and cell surface
expression to variable degrees [6]. However, we can only say for
certain that the two mutations in the GPCR proteolytic site
(GPS) domain, C346S and W349S, cause a brain malformation
through trapping the mutated proteins in the endoplasmic
reticulum [6].
Most recently, we have discovered that the ligand of GPR56 is
collagen III [7]. In this report, we aim to identify and characterize
the binding domain of GPR56 to collagen III. Although the N-
terminal extracellular domain of GPR56, GPR56
N, is heavily
glycosylated, we provide strong evidence that glycosylation is not
required for ligand binding. Moreover, disease-associated muta-
tions in the ligand binding domain completely eliminate its ligand
binding ability, revealing the molecular mechanism for GPR56-
related brain malformation.
Results
GPR56
N binds specifically to collagen III in the
developing brain
We have previously shown that GPR56
N binds a putative ligand
in the meninges and pial basement membrane and subsequently
demonstrated that the ligand of GPR56 is collagen III in the
developing brain [7,8]. To examine the binding specificity of
GPR56
N to collagen III, we performed a putative ligand binding
assay in wild type, Col3a1
2/2, and Gpr56
2/2 brains. Both
Col3a1
2/2 and Gpr56
2/2 mice are true null allele mutants
(Fig. 1B) [8]. Deletion of Gpr56 has no effect on the expression of
collagen III protein and GPR56
N binding patterns (Fig. 1C and F),
whereas loss of Col3a1 completely removed the binding of
GPR56
N (Fig. 1E). Taken together, our data supports that
GPR56
N binds specifically to collagen III in the developing brain.
The ligand binding domain of GPR56 is within aa 27–160
We have previously shown that the deletion of aa 93–143
completely abolished the ligand binding ability of GPR56,
suggesting that the ligand binding domain lies in the most N-
terminal region of GPR56
N [8]. To identify the ligand binding
domain of GPR56, we engineered a series of truncated GPR56
N-
hFc fusion protein constructs by gradually trimming GPR56
N
from both the N- and C-terminus (Fig. 2A). The constructs were
transiently expressed in HEK-293T cells to generate fusion
proteins that were naturally glycosylated (Fig. 2B). The concen-
trated fusion proteins were then used for ligand binding assays on
embryonic day (E) 14.5 mouse cortices. We were able to observe
putative ligand binding with all of the fusion proteins except the
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29818ones containing aa 27–142 and aa 49–160 (Fig. 2C–J). The
shortest fragment that has full ligand binding capacity was the
fusion protein containing aa 27–160 (Fig. 2H).
To further verify the putative ligand binding data, we carried
out a series of co-immunoprecipitation (co-IP) experiments using
meningeal fibroblasts as the ligand source. We failed to detect
Figure 1. GPR56
N binds specifically to collagen III in the developing brain. (A–C) Immunostaining of collagen III in E14.5 mouse brain
sections of wild type, Col3a1
2/2, and Gpr56
2/2 revealed an expression of collagen III (red) in the meninges and pial basement membrane of wild type
and Gpr56
2/2 brains. Deletion of Col3a1 completely abolished the expression of collagen III. Scale bar, 100 mm. (D–F) Strong GPR56
N binding was
detected in meninges and pial basement membrane of wild type and Gpr56
2/2, but not Col3a1
2/2 mouse brains. Nuclear counterstain was
performed with Hoechst 33342 (blue). Scale bar, 200 mm.
doi:10.1371/journal.pone.0029818.g001
Figure 2. The ligand binding domain of GPR56. (A) The truncated GPR56
N-hFc fusion protein constructs are schematically shown, as well as the
full length GPR56 protein with its identified N-glycosylation sites. (B) The fusion constructs were transfected into HEK-293T cells. Secreted proteins in
the conditioned media were collected, concentrated, and verified by western blot. (C–J) Putative ligand binding on E14.5 mouse cortex. The shortest
fragment with a specific binding pattern (green) is the truncated GPR56
N-hFc fusion protein containing aa 27–160 (H). Nuclear counterstain was
performed by Hoechst 33342 (blue). Scale bar, 200 mm. (K) The binding of collagen III and various truncated GPR56
N-hFc was confirmed by co-IP.
Anti-hFc immunoblot served as a loading control.
doi:10.1371/journal.pone.0029818.g002
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aa 49–160, despite comparable fusion protein levels (Fig. 2K).
Altogether, our data supports the conclusion that the fragment of
aa 27–160 contains the ligand binding domain of GPR56.
N-glycosylation is not required for ligand binding
The ligand binding domain of GPR56 contains two N-
glycosylation sites, N39 and N148. To investigate whether
glycosylation at each of these two sites is required for ligand
binding, we generated two mutations, N39Q and N148Q, in the
fragment of aa 27–160 to individually remove the corresponding
N-glycosylation (Fig. 3A). The mutant proteins were detected in
the conditioned media of transiently transfected cells and, as
expected, both mutations abolished one N-glycosylation site
resulting in a protein that migrates faster on SDS-PAGE
(Fig. 3B). The mutant fusion proteins were concentrated from
the conditioned media and used for both the putative ligand
binding assay and co-IP experiments. Both mutants retained a
ligand binding capacity comparable to the wild-type protein,
suggesting glycosylation of GPR56 is not necessary for ligand
binding (Fig. 3C–F).
Disease-associated mutations abolish ligand binding
The four reported disease-associated mutations in the ligand
binding domain are R38Q, R38W, Y88C, and C91S. We have
previously shown that these four mutations decreased mutant
proteins expression on the cell surface and its secretion into the
conditioned media [6]. It is not clear, however, how each of the
four missense mutations completely demolishes the receptor
function. To study whether these mutations also affect ligand
binding, we generated individual mutant ligand binding domains
by site-directed mutagenesis in the pFUSE-hFc2 construct
containing aa 27–160 of GPR56 (Fig. 4A). We were able to
detect the fusion mutant proteins in the conditioned media of the
transfected cells (Fig. 4B). The mutant fusion proteins were
concentrated from the conditioned media and used for the
putative ligand binding assay and co-IP experiments. None of
these four mutant proteins could bind the ligand in both the
putative ligand binding assay and co-IP experiments, proposition-
ing that the four missense mutations completely killed the ligand
binding ability of GPR56 (Fig. 4C–H).
Disease-associated mutations fail to rescue collagen III-
mediated neural migration inhibition
We have thus far demonstrated a loss of interaction between
mutant GPR56 proteins and collagen III by tissue binding and
protein pull down assays. However, the functional implication of
this observation is not clear. We have previously shown that
collagen III inhibits neural migration via GPR56 and that wild
type GPR56
N can rescue this inhibition [7]. To further investigate
the impact of BFPP-associated mutations on the receptor function,
we performed a neurosphere migration assay to examine whether
the four BFPP-associated mutations - R38Q, R38W, Y88C, and
C91S - functionally abolish receptor-ligand interaction. As
expected, in contrast to the wild type GPR56
N, none of the four
mutant proteins were able to reverse the collagen III-mediated
neural migration inhibition (Fig. 5).
Wild type human GPR56
N binds to both human and
mouse collagen III, whereas mutant GPR56 proteins lose
their ligand binding ability
We have thus demonstrated that mouse GPR56 binds to both
mouse and human collagen III. To study whether the interaction
can extend to the human GPR56 protein, we constructed a human
GPR56
N-hFc fusion protein (hGPR56
N-hFc) and the correspond-
ing BFPP-associated mutants: R38Q, Y88C, and C91S. We first
performed co-IP experiments using purified human collagen III.
As expected, we can only detect collagen III in wild type
hGPR56
N but not in the mutant hGPR56
N co-IP protein
complexes (Fig. 6B). We next examined the tissue binding activity
Figure 3. Glycosylation mutations of GPR56 did not affect its ligand binding. (A) The schematic representation of two separate N-
glycosylation mutations within the GPR56 ligand binding domain is shown. (B) Secreted fusion proteins in the conditioned media were collected,
concentrated, and verified by western blot. (C–E) Putative ligand binding on E14.5 mouse cortex. The N-glycosylation mutation did not impair GPR56
ligand binding (green). Nuclear counterstain was performed by Hoechst 33342 (blue). Scale bar, 200 mm. (F) The binding ability of the two N-
glycosylation mutants to collagen III was confirmed by co-IP. Anti-hFc immunoblot served as a loading control.
doi:10.1371/journal.pone.0029818.g003
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type hGPR56
N binds to mouse collagen III whereas mutant
hGPR56
N fails to exhibit any binding activity on mouse
embryonic brains. Taken together, our data suggests that there
is no species restriction between mouse and human in regards to
the interaction of GPR56 and collagen III.
Discussion
GPR56 is a particularly distinct member of the adhesion
GPCRs since its mutations are associated with a devastating
human brain malformation called BFPP [3,9,10]. There are a total
of eleven reported null allele missense mutations associated with
BFPP, two of which reside in the GPS domain and cause brain
malformation by demolishing the autoproteolytic process, thus
trapping the mutant proteins in the endoplasmic reticulum [5,10].
A recent study by Lin’s group indicates that mutations in the tip of
GPR56
N likely render the receptor null status by affecting their
binding to a putative cellular ligand in HT1080 cells [11]. Here,
we show four mutations in the tip of GPR56
N impair the receptor
function by aborting its ligand binding ability, in addition to
affecting the receptor cell surface expression.
GPR56 is cleaved at aa 382 via a GPS-mediated autoproteolytic
process [6,12,13]. Although the cleaved GPR56
N lacks a
transmembrane sequence, it is expressed on the cell surface via
an unknown mechanism [6]. In addition, GPR56
N is secreted into
the conditioned media [6,13]. We previously showed that the four
missense mutations on the tip of GPR56
N (R38Q, R38W, Y88C,
and C91S) affect the secretion of GPR56
N into the conditioned
media [6]. In this study, we were able to detect secreted mutant
proteins in their short forms. The possible explanations could be
either that the pFUSE-hFc2 vector was more efficient in driving
protein expression/secretion since it uses the IL2 signal peptide
sequence or that replacing aa 160–382 with the large hFc
fragment facilitated the shedding of the fusion protein.
GPR56 functions in a capacity to mediate cell-extracellular
matrix interaction. Our recent finding demonstrates that collagen
III is the ligand of GPR56 in the developing brain [7]. Collagen III
is a major collagen in the connective tissues with integrin a1b1 and
a2b1 both serving as it’s receptors [14,15]. In this report, we
identified the binding domain of GPR56 to collagen III. Since
there is no consensus amino acid sequence between integrin
a1b1/a2b1 and GPR56, it is likely that GPR56 binds to a
different region of collagen III.
In addition to its vital function in brain development, GPR56
also plays an important role in tumor growth and metastasis.
GPR56 was originally cloned by two independent groups in
1999, one using a degenerative PCR approach and the other
through differential display in high and low metastatic melanoma
cell lines [16,17]. The latter group revealed that GPR56 is
significantly down regulated in high metastatic melanoma cell
lines, indicating a possible role of GPR56 in tumor metastasis
[17]. It was subsequently demonstrated that GPR56 inhibits
tumor growth/metastasis, likely by regulating VEGF production
and tumor angiogenesis [13,18]. In addition, they showed that
GPR56 binds to TG2, a major crosslinking enzyme in the
extracellular matrix, at aa 108–177 [13,18]. Although knockdown
of TG2 did not lead to an increase of VEGF, deleting the TG2
binding domain led to enhanced angiogenesis and tumor growth
[18]. There is some overlap between the collagen III and TG2
binding domains on GPR56. It is highly desirable to reveal the
crystal structure of these two binding domains in order to fully
understand how GPR56 dynamically interacts with both collagen
III and TG2 in both the developing brain as well as tumor
growth and metastasis.
Figure 4. Disease-associated GPR56 abolished its ligand binding. (A) GPR56
N-hFc aa 27–160 schematic. The positions of the disease-
associated mutations within the ligand binding domain are shown. (B) Secreted fusion proteins in the conditioned media were collected,
concentrated, and verified by a western blot. (C–G) Putative ligand binding on E14.5 mouse cortex. Each of the four disease-associated mutations
completely killed the receptor-ligand binding ability in contrast to the strong binding signal (green) displayed by the wild type fusion protein (C).
Nuclear counterstain was performed with Hoechst 33342 (blue). Scale bar, 200 mm. (H) The impaired binding of disease-associated mutants to
collagen III was confirmed by co-IP. Anti-hFc immunoblot served as a loading control.
doi:10.1371/journal.pone.0029818.g004
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Ethics Statement
Experiments were performed in accordance with National
Institutes of Health guidelines for the care and use of laboratory
animals, and with the approval of the Animal Care and Use
Committee of Children’s Hospital Boston.
Mice
Col3a1 knockout mice were obtained from the Jackson
Laboratory with the strain name C.129S4 (B6)-Col3a1tm1Jae/J
in a BALB/c background. The Gpr56 knockout mice, kindly
provided by Genentech, were produced in collaboration between
Genentech and Lexicon Genetics to analyze the function of ,500
secreted and transmembrane proteins. All animals were treated
according to the guidelines of the Animal Care and Use
Committee of Children’s Hospital Boston (approval ID: A3303-
01).
Histology and Immunohistochemistry
Histology analysis was carried out as previously described [7,8].
Frozen sections were collected on a cryostat. Sections were
incubated with rabbit anti-human collagen III antibody (Lifespan
Biosciences). Primary antibodies were visualized by appropriate
fluorophore-conjugated secondary antibodies. Images were cap-
tured using a Nikon 80i upright microscope. Representative
photographs were obtained with the same exposure setting for
both the control and mutant.
Figure 5. Mutant mouse GPR56 proteins failed to rescue collagen III-mediated neural migration inhibition. (A–G) Neurospheres were
generated and plated on PDL-coated dishes in regular neurosphere culture medium. After 20 h, the cultures were changed to experimental medium
containing collagen III (84 nM) with or without wild type or mutant GPR56 proteins (90 nM), or carrier solution (acetic acid). Representative images
are shown. Scale bar, 100 mm. (H) The degree of collagen III-mediated migration inhibition was quantified as a percentage of the migrating
neurospheres. Data are presented as mean 6 SD, n=3 for each group. *P,0.01, Student t test.
doi:10.1371/journal.pone.0029818.g005
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The human IgG Fc-tagged mouse GPR56
N (mGPR56
N-hFc)
and its truncated fragments were constructed in pcDNA3.1-zeo
vector (Invitrogen). The hFc tag was cloned into the Xho I/Apa I
sites of the vector. Mouse GPR56
N and its truncated fragments,
including the GPR56 signal peptide sequence, aa 1–26, were
generated by PCR using primers listed in Table S1 and
subsequently fused to hFc by inserting into the Nhe I/Xho I sites.
Our previous data showed that BFPP-associated mutations affect
protein intracellular trafficking and secretion [6]. To increase
protein secretion, we cloned the mouse GPR56 ligand binding
domain, aa 27–160, into the pFUSE-hFc2 vector (Invivogen) that
contains the IL2 signal peptide sequence. N-glycosylation mutations
and BFPP-associated mutations were created by site-directed
mutagenesis using the QuikChange II XL Site-Directed Mutagen-
esis kit (Stratagene), as previously described [6]. The primers used
for the site-directed mutagenesis are listed in Table S2.
The human IgG Fc-tagged human GPR56
N (hGPR56
N-hFc) was
also constructed in pFUSE-hFc2 vector (Invivogen) between Nco1
andBglIIsites.TheprimersusedforhumanGPR56
NPCRarelisted
in Table S3. BFPP-associated mutations were created by the same
approach described above using the primers listed in Table S4.
Generation of hFc fusion protein and putative ligand
binding assay
Each of the above GPR56
N-hFc expression constructs was
transiently transfected into HEK-293T cells (obtained from
ATCC). The culture media was changed to serum-reduced
OPTI-MEM 24 hours after transfection. The conditioned media
was harvested 48–72 hours later, and concentrated as previously
described [8]. For the neurosphere migration assay, the mouse
GPR56 27–160 hFc wild type and mutant proteins were purified
through protein A column (GE Healthcare).
Time pregnant wild type mice in the CD-1 background were
ordered from Charles River. Embryonic day (E) 14.5 wild type
mouse brain sections were obtained at 12 mm in thickness on a
cryostat (Leica). Equivalent amounts of fusion proteins were used as
probesto examine their bindingability to mouse brainsections. The
localization of GPR56
N-hFc proteins were visualized by fluorescein-
conjugated rabbit anti-human IgG antibody (Thermo Scientific).
Co-immunoprecipitation (co-IP) and western blot
analysis
Co-IP for mouse GPR56
N and collagen III and immunoblotting
were done as previously described, using meningeal fibroblasts as
the ligand source [7]. Purified human collagen III (Abcam) was
used in co-IP to test the interaction of human GPR56
N and
collagen III. Protein-G beads were used to pull-down the
GPR56
N-hFc protein complex. Immunocomplexes were subjected
to SDS-PAGE and western blot using rabbit anti-human collagen
III antibody (Lifespan Biosciences), and rabbit anti-human IgG Fc
antibody (Thermo Scientific) following standard protocols.
Migration assay
Neurosphere generation and migration assay were done as
described previously [7]. The neurospheres were plated in a 48-
well dish precoated with 100 mg/ml poly-D-lysine (PDL) and
culturedinneuronculturemediumovernight.Aftertheneurospheres
adhered to PDL substrate, the culture medium was then replaced
with one of the experimental mediums: neuron culture medium with
84 nM purified human collagen III (Abcam) with or without 90 nM
wild type or mutant GPR56
N, or with carrier solution (acetic acid) as
control.Theneurosphereswereimagedandthenumberofmigrating
neurospheres was quantified after a 2 day culture. It is worth noting
that Abcam only guarantees the quality of purified or recombinant
human collagen III by western blot analysis. We prescreened the
biological function of each lot by a neural migration assay prior to a
bulk order, since there is a significant variation between each lot.
Supporting Information
Table S1 Primers for mouse truncated GPR56
N-hFc cloning.
(DOC)
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N-hFc site-directed muta-
genesis.
(DOC)
Table S3 Primers for human GPR56
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Figure 6. Human GPR56 binds to both mouse and human
collagen III and disease-associated GPR56 mutations abolish
their ligand binding ability. (A) Human GPR56
N-hFc aa 27–382
schematic. The positions of the disease-associated mutations are
shown. (B) Co-IP of human GPR56
N and purified human collagen III.
Collagen III was detected in GPR56 IP complex, but not in mutant
GPR56 complexes. Anti-hFc immunoblot served as a loading control.
(C–F) Putative ligand binding of human GPR56
N-hFc on E14.5 mouse
cortex. Strong binding signal was detected (green) with wild type
human GPR56
N-hFc protein staining, whereas a loss of signal occurred
in mutant proteins. Nuclear counterstain was performed with Hoechst
33342 (blue). Scale bar, 200 mm.
doi:10.1371/journal.pone.0029818.g006
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